In Brief: Summit Technology/LCA-Vision
This article was originally published in The Gray Sheet
Executive Summary
Summit Technology/LCA-Vision: Summit agrees to divest its chain of photorefractive keratectomy (PRK) Vision Centers to LCA-Vision under an agreement announced July 23. Under the terms of the deal, LCA will issue about 17 mil. shares of its common stock for all of Refractive Centers International -- the Summit subsidiary which owns and operates the Vision Center business, including 19 centers across the U.S. The deal is valued at about $46.8 mil. based on LCA's July 22 closing price of 2-3/4. The transaction, still subject to standard regulatory conditions, also is awaiting "the closing of bank financing by LCA," Summit says. Summit announced its plan to either sell or spin off the business earlier this year due to its drain on company resources and its negative impact on customer relations with ophthalmic surgeons ("The Gray Sheet" Feb. 3, In Brief). Upon completion of the sale, LCA "will have over 40 vision correction centers in the U.S., Canada and Europe, making it one of the nation's largest providers of laser vision correction," Summit notes...
You may also be interested in...
Staar Surgical To Offer Ophthalmic Surgeons Stake In Laser-Center Chain
Staar Surgical will allow certain ophthalmic surgeons to purchase an equity stake in its chain of refractive laser eye surgery centers, the firm says.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.